Schedule 13D/G History

Foresite Capital Fund IV, L.P. - Significant Ownership

Signature - Title: Foresite Capital Fund IV, L.P. - James Tananbaum, Managing Member of the General Partner
Location: San Francisco, CA
Summary: This page shows a list of all the recent SCHEDULE 13D/G filings made by Foresite Capital Fund IV, L.P..

Significant Ownership of Foresite Capital Fund IV, L.P.

Sym	Company	Class	Ownership	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
LYEL	Lyell Immunopharma, Inc.	Common Stock, par value $0.0001	6.7%	$10.5M		19.5M		James Tananbaum	Dec 31, 2024
MAZE	Maze Therapeutics, Inc.	Common Stock, par value $0.001	5.6%	$27.1M		2.46M		James Tananbaum	Jan 31, 2025

Schedules 13D/G Reported by Foresite Capital Fund IV, L.P.:

Sym	Target	Class	Ownership	Change	Current Shares	Change	Value	Reporting name	Form	Report Period	Date Filed

* An asterisk sign (*) next to the price indicates that the price is likely invalid.